Lead Global Patient Safety Asset – Rare Diseases

Ipsen Pharma (SAS); Paris; Hybrid; EUR 140,000 - 180,000; Full time

Job summary

Ipsen Pharma (SAS) seeks a Global Patient Safety Asset Lead, Rare Diseases to represent GPS for one or more products. The role leads safety surveillance, risk management, and cross‑functional collaboration across Clinical Development and Asset Teams to ensure safe and effective use in development and on the market.

Ideal candidates hold an MD with years of clinical experience, proven leadership of Safety and Clinical Development teams, and demonstrated experience with regulatory submissions and

Qualifications

• MD with years of clinical experience and medical judgment.
• Experience leading Clinical Development Teams is ideal.
• Pharmaceutical industry experience in clinical development.
• Experience leading cross-functional Global Product, Safety and Clinical Development Teams.
• Fluent in English; French language preferred.

Responsibilities

• Represent GPS as a member of Global Asset Team for one or more products.
• Lead safety surveillance and risk minimization actions for safety profile.
• Provide safety expertise for regulatory submissions and PSURs/DSURs.
• Drive cross-functional collaboration within GPS and asset teams.
• Lead signal detection and signal evaluation activities.
• Support safety decisions in benefit‑risk assessments.
• Provide TA and product-specific training within GPS.

Skills

Clinical development

Cross-functional leadership

Pharmacovigilance

Regulatory submissions

Medical judgment

Leadership

Education

MD (Medical Doctor)

Job description

Ipsen Pharma (SAS) seeks a Global Patient Safety Asset Lead, Rare Diseases to represent GPS for one or more products. The role leads safety surveillance, risk management, and cross‑functional collaboration across Clinical Development and Asset Teams to ensure safe and effective use in development and on the market.

Ideal candidates hold an MD with years of clinical experience, proven leadership of Safety and Clinical Development teams, and demonstrated experience with regulatory submissions and